We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Stresses Risk Management, Testing in New Gene Therapy IND Guidance
FDA Stresses Risk Management, Testing in New Gene Therapy IND Guidance
The FDA is seeking feedback on the chemistry, manufacturing and controls information that it wants drugmakers to include in INDs for gene therapies containing microbial vectors.